Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction

• Published in: Clinical research in cardiology Vol. 108; no. 12; pp. 1386 - 1393
• Main Authors: Sörensen, Nils A., Nikorowitsch, Julius, Neumann, Johannes T., Rübsamen, Nicole, Goßling, Alina, Hartikainen, Tau S., Blankenberg, Stefan, Westermann, Dirk, Zeller, Tanja, Karakas, Mahir
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2019; Springer Nature B.V
• Subjects: Aged; Biomarkers - blood; Cardiology; Emergency medical services; Female; Health risk assessment; Heart attacks; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Mortality; Myocardial infarction; Myocardial Infarction - blood; Myocardial Infarction - diagnosis; Myocardial Infarction - mortality; NCT; NCT02355457; Original Paper; Patients; Prediction models; Predictive Value of Tests; Prognosis; Receptors, Urokinase Plasminogen Activator - blood; Risk Assessment; Risk Factors; Thrombolytic drugs; Time Factors; U-Plasminogen activator; Urokinase; ACS; Risk prediction; Soluble urokinase-type plasminogen activator receptor (suPAR); Mortality
• ISSN: 1861-0684; 1861-0692; 1861-0692
• DOI: 10.1007/s00392-019-01475-1

Background Early risk stratification of patients with suspected acute myocardial infarction (AMI) constitutes an unmet need in current daily clinical practice. We aimed to evaluate the predictive value of soluble urokinase-type plasminogen activator receptor (suPAR) levels for 1-year mortality in patients with suspected AMI. Methods and results suPAR levels were determined in 1314 patients presenting to the emergency department with suspected AMI. Patients were followed up for 12 months to assess all-cause mortality. Of 1314 patients included, 308 were diagnosed with AMI. Median suPAR levels did not differ between subjects with AMI compared to non-AMI (3.5 ng/ml vs. 3.2 ng/ml, p  = 0.066). suPAR levels reliably predicted all-cause mortality after 1 year. Hazard ratio for 1-year mortality was 12.6 ( p  < 0.001) in the quartile with the highest suPAR levels compared to the first quartile. The prognostic value for 6-month mortality was comparable to an established risk prediction model, the Global Registry of Acute Coronary Events (GRACE) score, with an AUC of 0.79 (95% CI 0.72–0.86) for the GRACE score and 0.77 (95% CI 0.69–0.84) for suPAR. Addition of suPAR improved the GRACE score, as shown by integrated discrimination improvement statistics of 0.036 ( p  = 0.03) suggesting a further discrimination of events from non-events by the addition of suPAR. Conclusions suPAR levels reliably predicted mortality in patients with suspected AMI. Study registration http://www.clinicaltrials.gov (NCT02355457).